The BiaB advantages over traditional methods of RNA manufacturing, include high throughput of high-quality pharmaceutical ...

Nearly 300,000 bottles of the drug, named Cinacalcet, were recalled and given a Class II recall risk level by the FDA.

Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company ...

The U.S. Food and Drug Administration has lifted a clinical hold on three cell therapies being developed by CARsgen ...

Aurobindo Pharma's CuraTeQ Biologics receives EMA GMP certificate for biosimilars, paving way for European approvals of three ...

The Cebu Provincial Government has signed a memorandum of agreement with the Department of Science and Technology and the Food and Drugs Administration to improve the quality of products produced by ...

Quotient Sciences, a leading global drug development and manufacturing accelerator, today announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), the first multi-product ...

The GMP inspection, conducted by EMA representatives from April 8-12, 2024, assessed mammalian and microbial drug substance ...

GMP compliant manufacturing of Gemini is a pivotal requirement for an Investigational New Drug (IND) application with FDA. The Company intends to utilize the current supply of Gemini for the ...